401. Triptolide inhibits the proinflammatory potential of myeloid-derived suppressor cells via reducing Arginase-1 in rheumatoid arthritis.
- Author
-
Zhao, Ziling, Huang, Huijie, Ke, Sikai, Deng, Bishun, Wang, Yun-xiu, Xu, Ning, Peng, Anping, Han, Guang, Liang, Enyu, He, Xiaohong, He, Qinglian, Ke, Pei-feng, Huang, Xian-zhang, and He, Min
- Subjects
- *
MYELOID-derived suppressor cells , *SUPPRESSOR cells , *RHEUMATOID arthritis , *T helper cells , *TRIPTOLIDE , *T cells - Abstract
• Inflammatory MDSCs are expanded in RA patients and arthritic mice. • The frequencies of MDSCs correlated strongly with disease severity and Th17 response in RA patients. • TPT inhibited the expression of arginase-1 in MDSCs. • TPT reduces the severity of arthritis and the frequency of MDSCs effectively. • MDSCs may function as a novel and effective therapeutic target for TPT in RA. Triptolide (TPT) is widely used in the treatment of rheumatoid arthritis (RA). However, its regulatory mechanisms are not fully understood. This study demonstrated that Myeloid-derived suppressor cells (MDSCs) were expanded in both RA patients and arthritic mice. The frequency of MDSCs was correlated with RA disease severity and T helper 17 (Th17) responses. MDSCs from RA patients promoted the polarization of Th17 cells in vitro , which could be substantially attenuated by blocking arginase-1 (Arg-1). TPT inhibited the differentiation of MDSCs, particularly the monocytic MDSCs (M-MDSCs) subsets, as well as the expression of Arg-1 in a dose dependent manner. Alongside, TPT treatment reduced the potential of MDSCs to promote the polarization of IL-17+ T cell in vitro. Consistently, TPT immunotherapy alleviated adjuvant-induced arthritis (AIA) in a mice model, and reduced the frequency of MDSCs, M-MDSCs and IL-17+ T cells simultaneously. The presented data suggest a pathogenic role of MDSCs in RA and may function as a novel and effective therapeutic target for TPT in RA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF